Prof. Ali Rezaie

Department of Gastroenterology

University of Calgary, Canada

Email: arezaie@ucalgary.ca

Qualifications

2007 M.Sc., University of Calgary

2004 M.D., Shahid Beheshti University of Medical Sciences

Publications (selected)

1. Rezaie A. "Absolute Versus Relative Risk: Can We get Persuaded by Information Framing?" Asian J Epidemiol 2012; 5(2): 62-65.
2. Rezaie A, Quan H, Fedorak RN, Panaccione R, Hilsden R. "Development and Validation of an Administrative Case-definition for Inflammatory Bowel Diseases." Can J Gastroenterol. 2012 Oct;26(10):711-7.
3. Rezaie A, Nikfar S, Abdollahi M. “Antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis”Arch Med Sci 2010; 6, 1: 49-55.
4. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. “Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis” World J Gastroenterol. 2009 Apr 7;15(13):1548-53.[PMID: 19340896].
5. Nikfar S, Rahimi R, Rezaie A, Abdollahi M. “A Meta-Analysis of the Efficacy of Sulfasalazine in Comparison with 5-Aminosalicylates in the Induction of Improvement and Maintenance of Remission in Patients with Ulcerative Colitis”Dig Dis Sci. 2008 Sep 4. [PMID: 18770034].
6. Rahimi R, Nikfar S, Rezaie A, Abdollahi M.”Comparison of Mesalazine and Balsalazide in Induction and Maintenance of Remission in Patients with Ulcerative Colitis: A Meta-Analysis”Dig Dis Sci. 2008 Aug 6. [PMID: 18683049].
7. Rahimi R, Nikfar S, Rezaie A, Abdollahi M.“Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis”Reprod Toxicol. 2008 Feb;25(2):271-5. Epub 2007 Dec 4. [PMID: 18242053].
8. Rahimi R, Nikfar S, Rezaie A,  Abdollahi M. “A meta-analysis of antibiotic therapy for active ulcerative colitis” Dig Dis Sci. 2007 Nov;52(11):2920-5. Epub 2007 Apr 6 [PMID: 17415632].
9. Zali M, Bahari A, Firouzi F, Daryani NE, Aghazadeh R, Emam MM, Rezaie A, Shalmani HM, Naderi N, Maleki B, Sayyah A, Bashashati M, Jazayeri H, Zand S.”Bone mineral density in Iranian patients with inflammatory bowel disease.” Int J Colorectal Dis. 2006 Feb 4; 1-9. PMID: 16463035.
10. Rezaie A, Eshghtork A, Zamani M, Dehghan G, Taghavi B, Nikfar S, Daryani N, Abdollahi M. “Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-beta1 in relation to disease activity in Crohn's disease patients.”Ann N Y Acad Sci. 2006 Dec; 1091: 110-22.
11. Rezaie A, Khalaj S, Shabihkhani M, Nikfar S, Zamani MJ, Mohammadirad A, Daryani NE, and Abdollahi M. " Study on the correlations among disease activity index and salivary transforming growth factor-beta1 and nitric oxide in ulcerative colitis patients” Ann N Y Acad Sci. 2007 Jan;1095:305-14.
12. Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases.”Dig Dis Sci. 2004 Nov-Dec; 49(11-12):1752-7. PMID: 15628697.
13. Rezaie A. Pouchitis: An Empirically Treated Disease in the Era of Evidence-based Medicine. International Journal of Pharmacology, 2011; 7: 550-551.
14. Rezaie A, Wong K, Gyenes G. “Pericardial tamponade in a patient with inactive ulcerative colitis”.Case Report Med. 2010:352417. Epub 2010 Feb 28.[PMID: 20204071].
15. Salari P, Rezaie A, Larijani B, Abdollahi M. “A systematic review on the impact ofn-3 fatty acids in bonehealth and osteoporosis”. Med Sci Monit. 2008 Mar;14 (3):RA37-44.